-
Mashup Score: 8ACCP Journals - 4 month(s) ago
Tiragolumab is a first-in-class, fully human IgG1/kappa anti-TIGIT monoclonal antibody that blocks the binding of TIGIT to CD155 (the poliovirus receptor). We summarize the pharmacokinetics (PK) data…
Source: accp1.onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103) - Garralda - The Journal of Clinical Pharmacology - Wiley Online Library https://t.co/T22hUfVlsC